Biomarkers

The importance of pathologically defined cohorts in Alzheimer’s disease trials

Plasma NfL as a biomarker for frontotemporal dementia

Diagnostic tools for neurodegenerative disease

Improving clinical trials for Alzheimer’s disease therapies

The role of metabolism in the development of Alzheimer’s disease

Comparing the performance of novel biomarkers across the spectrum of Alzheimer’s disease

Using plasma biomarkers in the diagnosis of Alzheimer’s disease

Which plasma biomarkers hold the most promise in Alzheimer’s Disease?

Blood-based biomarkers for Alzheimer’s disease screening

Plasma p-Tau181 and p-Tau231 offer complementary information in Alzheimer’s